Souhaila S. Enaili

Dr. Souhaila S. Enaili

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
Amany mohamed HamedAmany mohamed Hamed
Amany mohamed Hamed
SESouhaila S. Enaili
Souhaila S. Enaili
WMWalaa I. Mohammed
Walaa I. Mohammed
AAAzza M. A. Abouelella
Azza M. A. Abouelella
Zeyad elsayed Eldeeb mohanaZeyad elsayed Eldeeb mohana
Zeyad elsayed Eldeeb mohana
ASAhmed M. El Saghir
Ahmed M. El Saghir
Background/Objectives: Inflammation is a crucial and complex mechanism that protects the body against infections. In our study, we propose to provide scientific evidence for the anti-inflammatory properties of 1,3,5-triazine derivatives. Methods: Initially, we ensured the safety of the three synthesized derivatives by administering graded doses of up to 2000 mg/kg intraperitoneally in Wistar rats. Thus, the three derivatives were considered generally safe. We also evaluated their ability to reduce carrageenan-induced rat paw edema. Results: Compounds 1, 2, and 3 demonstrated stronger anti-inflammatory activity than indomethacin (10 mg/kg), achieving maximum inhibition at the fourth hour with percentages of 96.31%, 72.08%, and 99.69%, respectively, at a dose of 200 mg/kg, compared to 57.66% for the standard drug. To explore the mechanism, levels of pro-inflammatory cytokines (TNF-α, IL-1α, IL-1β, IL-6, CRP) and oxidative stress markers were measured in paw tissue. All three compounds significantly reduced these markers more effectively than indomethacin and enhanced antioxidant levels (SOD and GSH) beyond those achieved by the standard treatment. Additionally, the compounds reduced COX-1 and COX-2 levels to values comparable to those in the normal (non-inflamed) control group. Conclusions: Compounds 1, 2, and 3 at doses of 200 mg/kg significantly (p < 0.05) inhibited the heat-induced hemolysis of red blood cell (RBC) membranes by 94.6%, 93.9%, and 95.2%, respectively, compared to 94.5% produced by indomethacin. Consequently, we concluded that 1,3,5-triazine derivatives are a safe antioxidant agent with significant anti-inflammatory activity.
1

Verified
Journal Article
Open access
PDF file
ASAhmed M. El Saghir
Ahmed M. El Saghir
Hamada HashemHamada Hashem
Hamada Hashem
SZSherif Ali Zohny
Sherif Ali Zohny
SESouhaila S. Enaili
Souhaila S. Enaili
AAAbdullah Alkhammash
Abdullah Alkhammash
HAHossameldin Ali Aziz
Hossameldin Ali Aziz
The present study aims to create spiro-N-(4-sulfamoyl-phenyl)-1,3,4-thiadiazole-2-carboxamide derivatives with anticancer activities. The in vitro anticancer evaluation showed that only the novel spiro-acenaphthylene tethered-[1,3,4]-thiadiazole (compound 1) exhibited significant anticancer efficacy as a selective inhibitor of tumor-associated isoforms of carbonic anhydrase. Compound 1 demonstrated considerable efficacy against the renal RXF393, colon HT29, and melanoma LOX IMVI cancer cell lines, with IC50 values of 7.01 ± 0.39, 24.3 ± 1.29, and 9.55 ± 0.51 µM, respectively. In comparison, doxorubicin exhibited IC50 values of 13.54 ± 0.82, 13.50 ± 0.71, and 6.08 ± 0.32 µM for the corresponding cell lines. Importantly, compound 1 exhibited lower toxicity to the normal WI 38 cell line than doxorubicin, with IC50 values of 46.20 ± 2.59 and 18.13 ± 0.93 µM, respectively, indicating greater selectivity of the target compound compared to the standard anticancer agent doxorubicin. Also, mechanistic experiments demonstrated that compound 1 exhibits inhibitory activity against human carbonic anhydrase hCA IX and XII, with IC50 values of 0.477 ± 0.03 and 1.933 ± 0.11 μM, respectively, indicating enhanced selectivity for cancer-associated isoforms over cytosolic isoforms hCA I and II, with IC50 values of 7.353 ± 0.36 and 12.560 ± 0.74 μM, respectively. Cell cycle studies revealed that compound 1 caused G1 phase arrest in RXF393 cells, and apoptosis experiments verified a substantial induction of apoptosis with significant levels of early and late apoptosis, as well as necrosis (11.69%, 19.78%, and 3.66%, respectively), comparable to those induced by the conventional cytotoxic agent doxorubicin, at 9.91%, 23.37%, and 6.16%, respectively. Molecular docking experiments confirmed the strong binding affinity of compound 1 to the active sites of hCA IX and XII, highlighting significant interactions with zinc-binding groups and hydrophobic residues. These findings underscore the target compound’s potential as a viable anticancer agent via targeting CA.

20 April 2026 in Materials Advances
Verified
Journal Article
Open access
PDF file
ESElders Khalaf Shokr
Elders Khalaf Shokr
SESouhaila S. Enaili
Souhaila S. Enaili
Moumen Samir KamelMoumen Samir Kamel
Moumen Samir Kamel
SESh. A. Elkot
Sh. A. Elkot
ASAhmed M. El Saghir
Ahmed M. El Saghir
SEShaimaa Elkot
Shaimaa Elkot
This work describes the synthesis of some novel organic compounds, along with the evaluation of their optoelectronic characteristics and potential for thermoelectric applications.

1 January 2026 in RSC Medicinal Chemistry
Verified
Journal Article
Closed access
ASAhmed M. El Saghir
Ahmed M. El Saghir
SESouhaila S. Enaili
Souhaila S. Enaili
AAAsmaa Abdul-Baset
Asmaa Abdul-Baset
MMMounir A. A. Mohamed
Mounir A. A. Mohamed
AHAmany M. Hamed
Amany M. Hamed
Novel sulfonamide derivatives as anti-fibrotic activity by reducing TGF-β1 and ECM markers.

22 July 2026 in Journal of Molecular Structure
Verified
Journal Article
Closed access
ASAhmed M. El Saghir
Ahmed M. El Saghir
SESouhaila S. Enaili
Souhaila S. Enaili
Amany mohamed HamedAmany mohamed Hamed
Amany mohamed Hamed
MMMonir A.A. Mohamed
Monir A.A. Mohamed
AAAsmaa Abdul‑Baset
Asmaa Abdul‑Baset